Tarsus Pharmaceuticals (TARS)

Executive Summary

Tarsus Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing novel therapeutics for ophthalmic conditions and other diseases with high unmet medical need. Its lead product, XDEMVY® (lotilaner ophthalmic solution) 0.25%, is the first and only FDA-approved treatment for Demodex blepharitis, providing a strong commercial foundation. The company is now advancing a pipeline targeting Meibomian gland disease (MGD), rosacea, and other conditions, leveraging its expertise in targeted therapies. Key pipeline assets include TP-03 for MGD and a lotilaner gel for papulopustular rosacea, both in Phase 2, as well as a recently initiated Phase 2 trial for ocular rosacea. With XDEMVY generating revenue and a focused pipeline, Tarsus is positioned to address multiple underserved patient populations, though near-term growth depends on commercial execution and pipeline progress.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 data readout for lotilaner in ocular rosacea60% success
• Q4 2026Initiation of Phase 3 trial for TP-03 in Meibomian gland disease70% success
• Q2 2026XDEMVY quarterly earnings update and commercial traction90% success